Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
Sign Up to like & getrecommendations! Published in 2020 at "Toxicology letters"
DOI: 10.1016/j.toxlet.2020.06.009
Abstract: Roxadustat is the first orally administered, small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that has been submitted for FDA regulatory approval to treat anemia secondary to chronic kidney diseases. Its usage has also been suggested… read more here.
Keywords: collagen; fibrosis; roxadustat attenuates; experimental pulmonary ... See more keywords